...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmaceutical statistics. >Comments on 'The potential for bias in the reporting of industry sponsored clinical trials' by Stephen Pyke et al. and 'Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry sponsored clinical trials' by James Matcham et al. Pharmaceutical Statistics.
【24h】

Comments on 'The potential for bias in the reporting of industry sponsored clinical trials' by Stephen Pyke et al. and 'Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry sponsored clinical trials' by James Matcham et al. Pharmaceutical Statistics.

机译：Stephen Pyke等人对“行业赞助的临床试验报告中可能存在的偏见”发表评论。 James Matcham等人的“在制药行业赞助的临床试验的报告和出版中统计学家的最佳实践建议”。药物统计。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

So long as we have private drug companies whose main duty is to the shareholder, we will have the potential for bias in reporting. However, this is also true in publicly funded universities, where positive findings may be rewarded with promotion and research grants. Thus, as always caveat emptor. It could even be argued that in the long run fraud will always be discovered and so it is not in drug companies' long-term commercial interests to promote biased results. It is my personal experience that the data handling and analysis of drug company trials is much more rigorous than those from many universities, but this is not where I would expect the biases to creep in.
机译：只要我们有私人制药公司，其主要职责是对股东负责，我们将有可能在报告方面产生偏差。但是，在公立大学中也是如此，在这些大学中，积极的发现可能会得到晋升和研究资助。因此，一如既往的告诫买主。甚至可以说，从长远来看，欺诈总是会被发现，因此提倡有偏见的结果不符合制药公司的长期商业利益。以我个人的经验，与许多大学相比，药物公司试验的数据处理和分析要严格得多，但这并不是我所期望的偏见蔓延的地方。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号